文献速递间质性肺疾病呼吸道感染

肺纤维化与COVID-19:抗纤维化治疗的潜在作用

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.
PubMed 文献 · Lancet Respir Med · 2020-05-15

本文综述了COVID-19与肺纤维化的关系,指出重症COVID-19与特发性肺纤维化(IPF)共享年龄、男性、高血压和糖尿病等危险因素。既往冠状病毒感染及COVID-19数据提示SARS-CoV-2感染后可能遗留显著纤维化后果,而抗纤维化治疗在IPF合并感染中的角色尚不明确,已有许可及在研抗纤维化药物在急性肺损伤和病毒性肺炎模型中经过评估,可能用于预防或治疗重症COVID-19及感染后纤维化。

要点

  • 重症COVID-19与IPF共享危险因素:年龄增长、男性、高血压和糖尿病。
  • SARS-CoV-2感染后可能出现显著纤维化后遗症。
  • 抗纤维化药物可能用于IPF患者预防重症COVID-19或治疗无IPF的重症患者。

核心结论

  • SARS-CoV-2感染后可能存在显著纤维化后果,抗纤维化治疗在IPF患者中继续或停止的科学依据尚不明确。
  • 可用或在研的抗纤维化治疗可能对IPF患者预防重症COVID-19、无IPF患者治疗重症COVID-19及预防感染后纤维化具有价值。

研究设计与样本

  • 本文为综述,未报告系统检索范围。

主要发现

  • 重症COVID-19的主要危险因素与IPF相同,包括年龄增长、男性、高血压和糖尿病等合并症。
  • 既往SARS和MERS等冠状病毒感染数据及COVID-19 emerging数据提示SARS-CoV-2感染后可能有显著纤维化后果。
  • 多种已许可和潜在抗纤维化化合物已在急性肺损伤和病毒性肺炎模型中经过评估。

临床怎么用

  • 对于IPF患者,需权衡抗纤维化治疗在SARS-CoV-2感染期间继续或停止的利弊,但依据尚不明确。
  • 抗纤维化治疗可能用于预防IPF患者发生重症COVID-19,或用于无IPF的重症COVID-19患者。
  • 需关注SARS-CoV-2感染后的纤维化后遗症,抗纤维化治疗可能具有预防作用。

局限性

  • 抗纤维化治疗在IPF合并SARS-CoV-2感染患者中的作用定义不清。
  • 证据多来自既往冠状病毒感染、模型研究和 emerging 数据,尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In December, 2019, reports emerged from Wuhan, China, of a severe acute respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By the end of April, 2020, over 3 million people had been confirmed infected, with over 1 million in the USA alone, and over 215 000 deaths. The symptoms associated with COVID-19 are diverse, ranging from mild upper respiratory tract symptoms to severe acute respiratory distress syndrome. The major risk factors for severe COVID-19 are shared with idiopathic pulmonary fibrosis (IPF), namely increasing age, male sex, and comorbidities such as hypertension and diabetes. However, the role of antifibrotic therapy in patients with IPF who contract SARS-CoV-2 infection, and the scientific rationale for their continuation or cessation, is poorly defined. Furthermore, several licensed and potential antifibrotic compounds have been assessed in models of acute lung injury and viral pneumonia. Data from previous coronavirus infections such as severe acute respiratory syndrome and Middle East respiratory syndrome, as well as emerging data from the COVID-19 pandemic, suggest there could be substantial fibrotic consequences following SARS-CoV-2 infection. Antifibrotic therapies that are available or in development could have value in preventing severe COVID-19 in patients with IPF, have the potential to treat severe COVID-19 in patients without IPF, and might have a role in preventing fibrosis after SARS-CoV-2 infection.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. George PM, Wells AU, Jenkins RG, et al. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020. PMID: 32422178. doi:10.1016/S2213-2600(20)30225-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。